Leading beyond regulatory approval: Opportunities for statisticians to optimize evidence generation and impact clinical practice

The role and value of statistical contributions in drug development up to the point of health authority approval are well understood. But health authority approval is only a true ‘win’ if the evidence enables access and adoption into clinical practice. In today's complex and evolving healthcare environment, there is additional strategic evidence generation, communication, and decision support that can benefit from statistical contributions. In this article, we describe the history of medical affairs in the context of drug development, the factors driving post-approval evidence generation needs, and the opportunities for statisticians to optimize evidence generation for stakeholders beyond health authorities in order to ensure that new medicines reach appropriate patients.